ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1969

FOXO1 Is Required for Human Osteoclast Differentiation

Sabarinadh Chilaka 1, Yannick Degboe 1, Iain McInnes 2 and Carl Goodyear3, 1Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom., Glasgow, Scotland, United Kingdom, 2Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, 3University of Glasgow, Glasgow, United Kingdom

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: differentiation, FOXO1 and tumor necrosis factor (TNF), monocytes, osteoclasts

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Osteoarthritis & Joint Biology – Basic Science Poster

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose:

Dysregulation of osteoclast differentiation and function is a feature of inflammatory arthropathies (IA). Multiple genes and signalling pathways have been associated with regulation of osteoclastogenesis. In particular, FOXO1, a member of the forkhead box O family of transcription factors, is implicated in many cell processes, including metabolism, signalling, ageing, stress, cell cycle, cell differentiation and as such is an intriguing candidate for osteoclast dysregulation in IA. Recent murine studies however provided conflicting data with regard to the role of FOXO1 in osteoclast differentiation (1, 2) and no data are available in human osteoclastogenesis. We therefore investigated the role of FOXO1 in human osteoclast differentiation.

Methods: Human CD14+ monocytes were isolated from human buffy coat samples using magnetic separation kit (Stemcell). Monocytes were differentiated into osteoclasts with M-CSF (25 ng/ml) and RANK-L (25 ng/ml) either in the presence or absence of a highly specific FOXO1 inhibitor (AS1842856; 0.5 uM for 3 days). To mimic inflammation-driven osteoclastogenesis, monocytes were grown in suboptimal RANK-L (1 ng/ml) medium for 4 days and on the 4th day TNF or supernatants from activated CD3+ T cells, were added in the presence or absence of FOXO1 inhibitor. Mature osteoclasts were stained with tartrate-resistant acid phosphatase and quantified by light microscopy.  Mineral-coated plates were used to assess the resorption activity. Gene expression was assessed by RT-qPCR. 

Results:

Inhibition of FOXO1 completely blocked both RANK-L driven and inflammation-driven (TNF or activated CD3+supernatant), osteoclast differentiation of human CD14+ monocytes and strongly inhibited osteolytic activity. FOXO1 inhibited cells were viable and had a macrophage-like phenotype. Kinetic studies revealed that FOXO1 plays a role in both the early cell fate decision and the late commitment phase of osteoclastogenesis; both inhibition during the first three days (pre-osteoclast stage) or later stage (day 4-7; committed osteoclast pre-cursors) was observed. Moreover, selective addition of AS1842856  on only day 1, clearly implicated FOXO1 during the earliest stages of osteoclast differentiation. Finally, gene expression analysis of major osteoclastogenesis-associated genes (M-CSFR, RANK and NFATC1) showed reduction upon treatment with AS1842856.

Conclusion: Our results suggest that FOXO1 is an essential transcription factor for human osteoclast differentiation. The ability to inhibit inflammation-driven osteoclastogenesis and osteolytic function indicates that this pathway may be viable therapeutic target in inflammatory arthropathies.

 References:

  1. Wang Y, Dong G, Jeon HH, Elazizi M, La LB, Hameedaldeen A, Xiao E, Tian C, Alsadun S, Choi Y, Graves DT. FOXO1 mediates RANKL-induced osteoclast formation and activity. J Immunol. 2015 Mar 15;194(6):2878-87.
  2. Tan P, Guan H, Xie L, Mi B, Fang Z, Li J, Li F. FOXO1 inhibits osteoclastogenesis partially by antagnozing MYC. Sci Rep. 2015 Nov 16;5:16835.

Disclosure: S. Chilaka, None; Y. Degboe, Celgene, 2; I. McInnes, Abbott, Bristol-Myers Squibb, Merck Sharp & Dohme, Pfizer, Roche., 2, 8, Abbvie, 5, AbbVie, 2, 5, 8, Amgen, 2, 5, 8, Astra Zeneca, 2, 5, AstraZeneca, 5, BI, 2, 5, BMS, 2, 5, 8, Boehringer Ingelheim, 5, Celgene, 2, 5, 8, Eli Lilly, 2, 5, 8, Janssen, 2, 5, 8, Leo, 5, Lilly, 5, Novartis, 2, 5, 8, Pfizer, 2, 5, 8, UCB, 2, 5, 8; C. Goodyear, Celgene, 2, AstraZeneca, 2, 5, MedAnnex, 2, 5, UCB, 2, Jannsen, 2.

To cite this abstract in AMA style:

Chilaka S, Degboe Y, McInnes I, Goodyear C. FOXO1 Is Required for Human Osteoclast Differentiation [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/foxo1-is-required-for-human-osteoclast-differentiation/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/foxo1-is-required-for-human-osteoclast-differentiation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology